Inventiva to Participate in Upcoming September Investor Conferences

On September 4, 2025, Inventiva, a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH), announced its participation in several upcoming investor conferences. These events aim to showcase the company’s progress and innovations in treating diseases with significant unmet medical needs.

Leading the presentations will be Inventiva's leadership team, who will engage with investors and stakeholders to share insights into the company's pivotal Phase 3 clinical trial of lanifibranor, a novel pan-PPAR agonist currently being evaluated for MASH—a chronic liver disease on the rise worldwide. The company will participate in the following key conferences:

- **H.C. Wainwright 27th Annual Global Investment Conference**: set for September 9, 2025, with a fireside chat scheduled at 3:00 PM EDT in New York City. - **8th Edition of the Lyon Pôle Bourse Forum**: taking place on September 23, 2025, in Lyon, France. - **KBC Life Sciences Conference**: on September 25, 2025, with a presentation at 5:00 AM EDT in Brussels, Belgium. - **Stifel 2025 Virtual Cardiometabolic Forum**: occurring on September 30, 2025, at 9:30 AM EDT in a virtual format. - **European MIDCAP Event 2025**: spanning September 30 to October 1, 2025, in Paris, France.

Inventiva is publicly traded on both the Euronext Paris and Nasdaq, providing an opportunity for broader market engagement and investment as it seeks to address significant healthcare challenges. Interested parties can learn more about Inventiva and its research efforts through its official website. For media and investor inquiries, the company has provided contact details for its corporate communications team.

Inventiva’s upcoming participation in various key investor conferences throughout September 2025 presents a notable opportunity for potential investors to engage with the company and gain critical insights into its growth trajectory and ongoing projects. As a clinical-stage biopharmaceutical firm specializing in therapies for metabolic dysfunction-associated steatohepatitis (MASH), Inventiva is well-positioned to capture investor interest, particularly as it advances its pivotal Phase 3 clinical trial for lanifibranor.

The participation in high-profile events, such as the H.C. Wainwright Global Investment Conference in New York and the European MIDCAP Event in Paris, allows Inventiva’s leadership to showcase their innovative approach and discuss their pivotal trial outcomes directly with investors. This is particularly significant given the increasing focus on MASH, a condition affecting millions worldwide and often leading to more severe liver diseases. Presenting at well-regarded conferences will enhance visibility and may facilitate dialogues with potential collaborators and investors.

For current shareholders and potential investors, this is an opportune time to monitor the announcements and presentations made during these conferences. Investors are advised to pay close attention to insights provided by management regarding trial progress, regulatory considerations, financial health, and strategic partnerships, as well as any shifts in market sentiment related to liver disease therapeutics.

Moreover, while Inventiva shows potential, due diligence is crucial. Investors should evaluate the company’s scientific data, competitive landscape, and financial performance leading up to these meetings. With the market continuing to evolve, Inventiva’s upcoming events offer a promising platform for informing future investment decisions, potentially unlocking value for those who engage during this pivotal time.